Kraus, Ludwig https://orcid.org/0000-0003-0707-7812
Kremmyda, Olympia
Bremova-Ertl, Tatiana
Barceló, Sebastià
Feil, Katharina
Strupp, Michael
Funding for this research was provided by:
Actelion Pharmaceuticals
Article History
Received: 2 November 2018
Accepted: 22 July 2019
First Online: 8 August 2019
Ethics approval and consent to participate
: Approval from the ethics committee board of the University of Munich was obtained for the study. All investigations were conducted according to the principles of the Declaration of Helsinki.
: Not applicable.
: L. Kraus, O. Kremmyda and K. Feil do not declare any conflicts of interest.T. Bremova-Ertl received speaker’s honoraria from Actelion and Sanofi-Genzyme.S. Barceló performed statistical analyses paid for by Actelion Pharmaceuticals.M. Strupp is Joint Chief Editor of the Journal of Neurology, Editor in Chief of Frontiers of Neuro-otology and Section Editor of F1000. He has received speaker’s honoraria from Abbott, Actelion, Auris Medical, Biogen, Eisai, Grünenthal, GSK, Henning Pharma, Interacoustics, Merck, MSD, Otometrics, Pierre-Fabre, TEVA, UCB. He is a shareholder of IntraBio. He acts as a consultant for Abbott, Actelion, AurisMedical, Heel, IntraBio and Sensorion.